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Summary
Type 1 diabetes (T1D) animal models such as the non-
obese diabetic (NOD) mouse have improved our un-
derstanding of disease pathophysiology, but many
candidate therapeutics identified therein have failed
to prevent/cure human disease. We have performed a
comprehensive evaluation of disease-modifying agents
tested in the NOD mouse based on treatment timing,
duration, study length, and efficacy. Interestingly,
some popular tenets regarding NOD interventions
were not confirmed: all treatments do not prevent dis-
ease, treatment dose and timing strongly influence ef-
ficacy, and several therapies have successfully
treated overtly diabetic mice. The analysis provides a
unique perspective on NOD interventions and sug-
gests that the response of this model to therapeutic*Correspondence: shoda@entelos.com
8These authors contributed equally to this work.interventions can be a useful predictor of the human
response as long as careful consideration is given to
treatment dose, timing, and protocols; more thorough
investigation of these parameters should improve
clinical translation.
T1D is an autoimmune disease afflicting 5%–10% (w1
million people) of the diagnosed diabetic population in
the United States (Centers for Disease Control and Pre-
vention, 2003). As T1D patients require life-long insulin
therapy and have a high risk of medical complications,
preventative or curative therapies are urgently needed.
Research in two spontaneous rodent models of T1D,
the NOD mouse and the bio-breeding (BB) rat, has im-
proved our understanding of pathogenesis and iden-
tified potential therapeutics (Anderson and Bluestone,
2004; Mordes et al., 2004). Despite some model-spe-
cific characteristics, hyperglycemia and diabetes onset
in both are attributed to leukocyte infiltration of the
pancreatic islets, ultimately leading to leukocyte-medi-
ated destruction of insulin-producing islet β cells (De-
lovitch and Singh, 1997; Mordes et al., 2004). Because
potential therapeutics identified in these models have
generally proven disappointing in clinical trials, the
models’ relevance has been questioned (Roep et al.,
2004). Hence, a retrospective analysis of NOD mouse
therapies and their applicability to human T1D is
strongly warranted.
In 2003, we initiated development of a T1D mathe-
matical model that represents natural disease pro-
gression in the female NOD mouse, to enable in silico
investigation of pathogenesis and treatment. In prepa-
ration for the modeling effort, we performed a compre-
hensive analysis of interventions tested in the NOD. The
results contradict some commonly held beliefs on T1D
interventions, identify potential contributors to poor
clinical trial results, and emphasize important criteria
for the design of future preclinical and clinical trials.
Analysis Method
Every attempt was made to review all NOD intervention
studies published from the strain’s inception (Makino et
al., 1980) through mid 2004, subject to our inclusion
criteria (Figure 1). We identified 463 agents or agent
combinations reported in 321 publications. Each agent
was assigned to one of eight categories: (1) costim-
ulation and adhesion, (2) cell infusions, (3) antigens, (4)
cell surface and cells, (5) immunomodulatory, (6) patho-
gens, (7) cytokines and hormones, and (8) environmen-
tal influences.
Data from each protocol were tabulated, including
treatment timing, dose, schedule, efficacy, and study
length. Efficacy was defined by the final (end of experi-
ment) author-reported change in diabetes incidence
(i.e., diabetic mice in treated versus control cohorts). To
minimize overrepresentation of frequently tested thera-
pies, repetitive protocols were excluded. Specifically,
within each paper, only one protocol was included for
Immunity
116Figure 1. Inclusion and Exclusion Criteria for
Intervention Studies
*Examples of nonspontaneous NOD models
include cyclophosphamide (CY) induced, strep-
tozotocin (STZ) induced, virally induced, irra-
diated, immunocompromised, transgenic, and
knockout models. Although inducible diabe-
tes models (e.g., CY or STZ) were not eval-
uated, studies reporting the effect of these
agents on spontaneous disease in female
NOD mice were included.(1) duplicate experiments, (2) dose-escalation experi-
ments, where a monotonic dose effect was observed,
and (3) experiments where treatment initiation times
and outcomes were identical but treatment or post-
treatment duration varied.
Comprehensive Analysis Illustrates
Disease Complexity
A subset of the analyzed agents is shown (Figure 2),
with the complete set available with this article online
(Figures S1–S8 in the Supplemental Data). We observed
three general findings. First, contrary to a popular belief
that most agents prevent disease in the NOD mouse,
many had no effect, and some even exacerbated dis-
ease. Second, agent efficacy frequently varied when
mice were treated at different ages (e.g., human CTLA-
4Ig), suggesting altered sensitivity in different disease
stages. Third, some therapies (i.e., human IL-11) might
differ in outcome depending on the length of postreat-
ment follow up.
The data may also be evaluated by agent to deter-
mine its strengths/weaknesses before advancing to
clinical trials. For example, the rationale for IL-10 is
supported by findings that multiple forms and early
protocols can be protective (Figure 3). Conversely, the
justified patient population may be restricted, as there
are no data on IL-10 treatment initiated in diabetic
mice. Further analyses of the comprehensive data set
are described below.
Disease Prevention throughout
the Prediabetic Period
A common tenet is that it is easy to prevent NOD T1D
if treatment is initiated early but more difficult later in
disease. Although some agents do prevent disease
when administered early, but not late (see the following
section), our analysis of diabetes prevention protocols
across agents (Supplemental Experimental Procedures)
suggests that therapeutic outcome is not dependent on
treatment onset time. Specifically, there was no differ-
ence in the probability of protection between treat-
ments initiated early (<4 weeks age) and late (R4
weeks age), 62.4% and 70.9% for early and late treat-
ments, respectively (P = 0.11). Moreover, the probability
of protection was comparable regardless of the age
used to define early versus late (e.g., 4, 6, 8, or 10
weeks) (Figure S9). Because the degree of protection
was not considered, we could not identify a trend to-
ward lesser efficacy with time. Additionally, our analysis
did not account for nonuniformity in protocols or under-
reporting of negative data. Nevertheless, the analysis
suggests that disease protection is feasible when treat-
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ding late, as well as early, prediabetic NOD mice.atterns of Time-Dependent Agent Efficacy
gents with time-varying effects on NOD T1D were
dentified (Table 1) and classified into three groups for
hich (1) earlier administration was better, (2) later ad-
inistration was better, and (3) prolonged treatment
as required for efficacy. To avoid interlaboratory vari-
bility, only agents demonstrating time-dependent effi-
acy changes within a paper were included in the
nalysis. Agents were also excluded if protocol vari-
bles (e.g., dose) differed between experiments.
As shown in Figure 4, the earlier administration was
etter group includes agents where initiating treatment
t an earlier stage of pathogenesis prevents diabetes,
hereas later treatment has no effect or exacerbates
e.g., anti-CD40L); it also includes agents that have no
ffect early but exacerbate late. The later administra-
ion was better category includes agents where later
reatment initiation is protective, whereas earlier treat-
ent has no effect or exacerbates (e.g., TNF-α), as well
s those where later treatment has no effect, but early
reatment exacerbates. Because early and late are rela-
ive terms, categories (1) and (2) are not mutually exclu-
ive. For example, anti-CD3 protected neonates, but
ot 3-week-old NOD mice (Hayward and Shriber, 1992);
lsewhere, anti-CD3 induced no or little protection in
rediabetic mice but remission in diabetic mice (Cha-
enoud et al., 1997). Finally, the category prolonged
reatment was required includes agents where longer
reatment duration converts a nonresponse to a protec-
ive response (e.g., anti-IL-12).
ccounting for Time-Dependent Changes
n Agent Efficacy
ime-dependent effects on diabetes incidence can re-
ult from numerous phenomena, as illustrated by anti-
D40L and TNF-α. Anti-CD40L was better with earlier
dministration, as initiating treatment at 3 weeks of age
as completely protective, whereas treatment initiated
t 9–10 weeks was only partially protective. One expla-
ation is that the CD40-CD40L pathway is critical for
isease initiation but less important later in disease
Balasa et al., 1997). Alternatively, the administered
ose may be ineffective in older mice, as the same
ose was used regardless of weight. Moreover, the
horter treatment duration in the later protocol may
ave impacted efficacy. If administering higher doses
r extending treatment duration in 9– to 10-week-old
ice resulted in a repeated observation of poor protec-
ion, it would strengthen the hypothesis that CD40-
D40L interaction is more critical in early disease; con-
ersely, protection would highlight dependency on
ose and treatment duration for anti-CD40L therapy.
Later administration was better for TNF-α, as early
Review
117Figure 2. Selected Interventions Tested in the NOD Mouse Plotted to Depict Treatment Timing, Duration, Efficacy, and Study Length
Agents and references are listed on the y axis. Timing and duration of treatment is indicated by a solid line (–); the follow-up period exceeding
the treatment period is indicated by a dashed line (--). Initiation and completion of each experiment are designated by symbols that reflect
efficacy. For treatment initiated in prediabetic NOD mice, treatment efficacy is broadly defined as “protects” (green circle), “no effect” (gray
square), or “exacerbates” (red triangle). For treatment initiated in diabetic NOD mice, efficacy is defined as “remission” (green inverted
triangle) or “no remission” (black x). Efficacy reflects the reported change in final (end of experiment) diabetes incidence. If mice were followed
to >40 weeks of age, the total experiment length is indicated in parentheses to the right of the graph. Because mice become diabetic at
different ages, the start time for protocols initiated in diabetic mice was set at 25 weeks of age, and the duration indicates length of
observational follow-up, relative to the 25 week start time. Based on data from Taconic and Jackson Laboratories, 90% of female NOD mice
that become diabetic exhibit hyperglycemia between 12 and 26 weeks of age.
*This protocol showed a significant delay in incidence of treated mice yet no difference in final incidence. (Akhtar et al., 1995; Ansari et al.,
2003; Han et al., 1996; Harrison et al., 1996; Iguchi et al., 1992; Jacob et al., 1990; Kim et al., 1997; Lenschow et al., 1995; Nicoletti et al.,
1999b; Reddy et al., 1990; Satoh et al., 1989; Seino et al., 1991; Tang et al., 2004; Wu et al., 2002; Yang et al., 1994).treatment exacerbated disease yet later treatment pro-
tected from disease (Figure 4). This behavior suggests
that TNF-α may impact a pathway(s) that is differenti-
ally modulated during disease progression, resulting in
opposing effects on diabetes incidence. As with anti-
CD40L, if trivial explanations for the time-dependent
changes can be eliminated, then these data might pro-
vide insight into the importance of particular pathways
at different disease stages.
Categorizing Disease-Exacerbating Agents
Treatment onset times resulting in disease exacerba-
tion were identified throughout pathogenesis (Figure
S10), suggesting that the rate or severity of diseaseprogression can be augmented at multiple stages. Ex-
acerbating agents could generally be categorized as
those targeting the T helper 1 versus 2 (Th1/Th2) bal-
ance, T cell costimulatory molecules, and immunizing
pathways (Figure 5). Agent-induced disease exacerba-
tion has improved understanding of disease pathogen-
esis and provided a caution for potential therapeutics.
Exacerbating Agents Elucidate Pathophysiology
For years, the Th1/Th2 paradigm provided a unifying
conceptual framework for many diseases, including
T1D. The paradigm posits that Th1 cells mediate T1D
pathogenesis, and therapies skewing the response to
a Th2 phenotype should be protective. Although some
Immunity
118Figure 3. All Reports on a Single Intervention, Exogenous IL-10
This figure illustrates all reports on a single intervention, namely exogenous IL-10. The data could lend support to advancing an agent to
human clinical trials (e.g., multiple IL-10 forms are protective; short treatment protocols can be protective). However, the data also indicate
knowledge gaps that may be critical for successful human translation (i.e., lack of data on IL-10 treatment initiated in diabetic NOD mice).
(Goudy et al., 2001, 2003; Nitta et al., 1998; Pennline et al., 1994; Slavin et al., 2001; Yang et al., 2002a; Zheng et al., 1997).Th2 skewing agents, including IL-4 and IL-10, were pro-
tective (Cameron et al., 2000; Goudy et al., 2003), oth-
ers such as anti-IL-12 and a BDC2.5 Th2 clone ex-
acerbated disease (Figure 5) (Fujihira et al., 2000; Poulin
and Haskins, 2000). The inconsistent results likely re-
flect that the Th1/Th2 paradigm is too simple to explain
T1D pathogenesis, partly because Th1/Th2 cytokines
h
h
T
r
f
pTable 1. Agents with Time-Dependent Effects
Result Agent Reference
Earlier administration was better CD3 Ab (Hayward and Shriber, 1992)
CD4 Ab (Makhlouf et al., 2004)
CD40L Ab (Balasa et al., 1997)
GAD Ab (Menard et al., 1999)
B cells (GAD-IgG) (Melo et al., 2002)
B cells (insulin B9-23-IgG) (Melo et al., 2002)
CsA (Mori et al., 1986)
CTLA-4 Ig + CD40L Ab (Makhlouf et al., 2004)
DCs (GM-CSF + IL-4) (Feili-Hariri et al., 2003)
DCs (IFN-gamma, NOD) (Shinomiya et al., 1999)
IFN-gammaR-IgG1 (DNA) (Chang and Prud’homme, 1999)
IL-10 (viral vector) (Yang et al., 2002a)
IL-10 (DNA) (Nitta et al., 1998)
IL-11 (Nicoletti et al., 1999b)
IL-12 Ab (Nicoletti et al., 1999a)
IL-12 (p40)2 (Trembleau et al., 1997)
IL-3 (Ito et al., 1997)
IL-4 (viral vector) (Cameron et al., 2000)
Irradiation (Takahashi et al., 2000)
Lisofylline (Yang et al., 2002b)
Nicotinamide (Yamada et al., 1982)
Sirolimus (Rapamycin) (Baeder et al., 1992)
S. mansoni (Zaccone et al., 2003)
Tolbutamide (Williams et al., 1993)
Later administration was better CD3 Ab (Chatenoud et al., 1997)
CTLA-4 Ab (Ansari et al., 2003)
TNF-alpha (Yang et al., 1994)
Prolonged treatment required CD4 Ab (Shizuru et al., 1988)
VCAM-1 Ab + α4-integrin Ab (Tsukamoto et al., 1995)
Dapsone (Peterson et al., 1997)
IL-12 Ab (p40) + IL-12 Ab (p70) (Fujihira et al., 2000)
IL-4 (viral vector) (Cameron et al., 2000)
IL-4 (Tominaga et al., 1998)
athogenic T cell activation and expansion unexpect-ave pleiotropic functions beyond modulation of T
elper phenotype (O’Shea et al., 2002). Thus, although
h1 cells play an important role in T1D, exacerbation
esults indicate that Th1/Th2 modulation alone is insuf-
icient to reliably treat disease.
Blocking T cell costimulatory molecules to impede
Review
119Figure 4. Three Patterns of Time-Dependent Behavior
Agents exhibiting time-dependent behavior could be broadly categorized as agents for which (1) earlier administration was better, (2) later
administration was better, and (3) prolonged treatment was required for the effect (Yang et al., 1994).edly resulted in disease exacerbation (Figure 5), sug-
gesting that costimulatory molecule blockade may in-
hibit protective pathways and/or augment exacerbating
pathways. In support of the former, the CD4+CD25+ reg-
ulatory T cell (Treg) population was significantly re-
duced in NOD mice treated with anti-B7-1 + anti-B7-2
antibodies and in the B7-1/B7-2 double knockout NOD
mouse, coincident with disease exacerbation (Salomon
et al., 2000). Additionally, differential efficacy observed
with B7-1 blockade (exacerbating) and B7-2 blockade
(protective) in NOD mice led to the finding that B7-1
may be sufficient for Treg development (Bour-Jordan et
al., 2004). Data from other experimental systems con-
firm that costimulatory molecules (B7/CD28/CTLA-4)
are critical for the survival, maintenance, and function
of Treg populations (Song et al., 2004; Lohr et al., 2003;
Tang et al., 2003). Additionally, other protective mecha-
nisms such as Th2 cell differentiation and anergy induc-
tion may depend on costimulatory molecules (Salomon
and Bluestone, 2001). Finally, data suggest that B7 ex-
pression on conventional T cells is required for their
suppression by Tregs (Paust et al., 2004). Thus, ex-
acerbating effects of costimulatory blockade have elu-
cidated protective pathways influenced by these mole-
cules in T1D.
Disease Exacerbation and Human Clinical Trials
Several studies have successfully immunized NOD mice
with T1D antigens (e.g., insulin, GAD65, and HSP60) to
prevent diabetes (Bach and Chatenoud, 2001); how-
ever, antigen immunization (e.g., GAD65 p509 and p524
peptides) has occasionally exacerbated disease (Figure
5). Disease exacerbation identifies a risk associated
with some forms of the antigen or with other immuniza-
tion variables (e.g., administration route and timing).
Agents demonstrating protective and exacerbating ef-
fects should be carefully scrutinized to determine the
reasons behind exacerbation before advancing to human
clinical trials (Rosenbloom et al., 2000).
Interventions Reported in Diabetic NOD Mice
As many T1D patients are identified only at diabetes
onset, agents assisting overtly diabetic subjects are
urgently needed. Of the 463 agents evaluated, only 23
protocols were initiated in diabetic NOD mice (Table 2,see Table S1 for references), yet 16 of 23 were consid-
ered successful. The reported successes argue for the
feasibility of treating overtly diabetic subjects and sug-
gest that further studies on diabetic mice are war-
ranted.
Variability in Diabetic Studies
Within the diabetic studies, we observed inconsisten-
cies in clinical measurements and reporting practices
that may complicate their utility for human clinical trials
(Table 3). For example, diabetic mice have been defined
by blood glucose levels exceeding 200, 300, or 400
mg/dl, with or without a requirement for multiple hyper-
glycemic measurements. The variability suggests that
“diabetic” mice may reflect animals at different stages
of disease progression with potentially different sensi-
tivity to therapeutic intervention. Not only does this
confound comparative analysis of agents, but it also
complicates the identification of correlative character-
istics of disease progression in mice versus humans
that could facilitate patient selection.
Another seemingly important variable is the delay be-
tween diabetes diagnosis and treatment initiation.
Three studies demonstrated that diabetic NOD mice
could be divided into responder and nonresponder
groups based on the length of this delay (Maki et al.,
1992; Makhlouf et al., 2004; Yamada et al., 1982). The
length of delay distinguishing responders and nonre-
sponders varied among the studies, which might relate
to colony or diabetes definition criteria. However, the
repeated observation suggests that time-dependent
sensitivity may be a general phenomenon. A better un-
derstanding of the mechanisms relating diabetes dura-
tion and efficacy could assist clinical translation, sug-
gesting that it should be reported in subsequent
diabetic NOD mouse studies.
Finally, treatment efficacy has been defined by mor-
tality, glycosuric status, different glycemic levels, and/
or independence from exogenous insulin (Table 3),
complicating agent comparisons. Moreover, some re-
porting procedures yield more information than others.
For example, posttreatment glycemic profiles for indivi-
dual mice indicate whether, when, and for how long
each mouse returns to normal glucose levels. This
quantitative and dynamic information may be helpful
Immunity
120Figure 5. Agents that Exacerbate Disease Generally Fall into Three Broad Categories: Those Targeting Th1/Th2 Balance, T Cell Costimulatory
Molecules, and Immunizing Pathways
There has been little appreciation for the number of agents that exacerbate disease in the NOD mouse as depicted in this figure. Knowledge
of these agents and their mechanisms of action can improve understanding of disease pathogenesis and provide a caution for potential
therapeutics. (Bendelac et al., 1987; Cetkovic-Cvrlje et al., 1997; Classen, 1996; Funda et al., 1998; Haskins and McDuffie, 1990; Healey et
al., 1995; Katz et al., 1995; O’Hara et al., 1996; Pakala et al., 1997; Peterson and Haskins, 1996; Poulin and Haskins, 2000; Thivolet et al.,
1991; Trembleau et al., 1995, 2000; Wilson et al., 2001; Yagi et al., 1991).in optimizing preclinical regimens or designing clinical
trials. Thus, we recommend standardization of re-
mission criteria and reporting of glycemic profiles in di-
abetic studies.
New-onset diabetic patients are likely to continue to
be an important segment of the clinical trial population,
suggesting critical guidance can be gained from studies
of overtly diabetic NOD mice. As such, we suggest that
the field would benefit from a closer examination of the
variability discussed above, ultimately resulting in the
development of standardized definitions and best prac-
tices (Beales et al., 1996) to increase the value of future
studies in diabetic mice.
Protocol Discrepancies in NOD versus Human Trials
Despite the successes in NOD mice, no disease-modi-
fying therapy has been approved in humans. Agents
tested in NOD mice and human patients were evaluated
for protocol discrepancies that might have contributed
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1o poor translation (Table S2). The following sections
iscuss the importance of therapeutic timing and dose
n translational T1D efforts, with emphasis on insulin
nd anti-CD3 therapies.
nsulin Tolerization Trials
nterest in inducing antigen-specific tolerance has
rompted several clinical trials, including whole insulin
dministration by various routes (Table 4). Although
OD insulin tolerization studies were promising, human
esults have been disappointing. NOD studies primarily
reated mice in early stages of disease, with few studies
erformed at later stages and none conducted on dia-
etic mice, although the possibility that exogenous in-
ulin administered for metabolic control might induce
olerogenic effects cannot be eliminated. Whereas the
atest NOD insulin tolerization initiation time was 10 or
2 weeks of age (Bergerot et al., 1997; Karounos et al.,
997), human trials included advanced prediabetic or
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121Table 2. Agents Used to Treat Diabetic Mice and Their Outcomes
Result Agent
Agents successfully inducing ALS
remission and/or survival ALS + Exendin-4
CD3 F(ab#)2
CD3 Ab
CD3 Ab (KT3)
TCR Ab
CD4 Ab
CD4 Ab + CD8 Ab
CD8 Ab
Tregs (CD4+CD25+)
CFA + splenocytes
HSP60 p277
ICAM-1/Ig
Nicotinamide
Insulin sc (viral)
Dapsone
Agents failing to induce remission ALS
and/or survival CD3 F(ab#)2 + CTLA-4 Ab
CD3 F(ab#)2 + TGF-beta Ab
CD4 Ab
CD8 Ab
CsA
CTLA-4 Ig + CD40L Ab
Exendin-4
LT-beta
Nicotinamide
Sirolimus (Rapamycin)diabetic patients. Because there are no data on treat-
ment of diabetic mice, a timing effect could contribute
to suboptimal clinical results.
In addition to timing, NOD data indicate that dose
can drastically influence efficacy. Given 1 mg insulin
orally, mice were partially protected, whereas no pro-
tection was observed at lower doses (0.01–0.1 mg)
(Zhang et al., 1991). Furthermore, the insulitis reduction
observed in 1 mg-treated versus control animals was
not observed at 5 mg, suggesting a loss of efficacy with
increasing dose. Dose dependency has also been ob-
served in an adoptive transfer model of diabetes (Berg-
erot et al., 1996). These studies suggest a critical dos-
ing window for efficacious insulin therapy.
In human trials, oral insulin was administered 2.5–7.5
mg/day (Pozzilli et al., 2000; Chaillous et al., 2000;
Skyler et al., 2005). Assuming 40–70 kg weight, patients
received only 0.03–0.2 mg/kg/day, whereas NOD mice
received roughly 50 mg/kg once or twice a week, as-
suming 20 g animals (Zhang et al., 1991). Comparably
low doses of insulin were used in human nasal insulin
trials (Harrison et al., 2004; Skyler et al., 2001), although
the dose required for nasal tolerization may be lower
than for oral tolerization. Parenteral insulin trials used a
10- to 100-fold lower dose per administration relative
to weight than corresponding NOD mouse studies (At-
kinson et al., 1990; Karounos et al., 1997; Muir et al.,
1995; Diabetes Prevention Trial--Type 1 Diabetes Study
Group, 2002). Suboptimal dosing is further supported
by lack of protection in NOD mice administered subcu-
taneous insulin at doses similar to those used in the
subcutaneous arm of the Diabetes Prevention Trial
(DPT), whereas a higher dose (20×) protected from dis-
ease (Karounos, 2003). Although our dosing compari-
son is based on weight, other factors can influence op-timal dose scaling (e.g., administration route, schedule,
and drug absorption/clearance). More detailed ap-
proaches to dose scaling (Mahmood, 1999) may be re-
quired; however, our preliminary evaluation (data not
shown) suggests that regardless of scaling approach,
significant discrepancies persist between insulin doses
used in NOD studies versus human trials. Indeed, de-
spite some indicators of positive therapeutic out-
comes, including induction of regulatory activity (Mo-
netini et al., 2004), a possible correlation between
autoantibody titer and responsiveness (Skyler et al.,
2005), and reduced insulin-specific T cell responses
(Harrison et al., 2004), most patients in the completed
trials responded poorly. The positive findings suggest
that antigen-specific therapies may enjoy increased
success with appropriate patient stratification. Alterna-
tively, further preclinical investigation of dose and tim-
ing, appropriately translated to the clinic, may increase
the success rate to a wider distribution of the patient
population.
Anti-CD3 Trials
Successful anti-CD3 treatment of diabetic mice has
motivated clinical trials in new-onset T1D patients. The
NOD mouse data reveal complex dependencies on
treatment timing and dose. A single high-dose (200–250
g) of anti-CD3 antibody 145-2C11 led to significant
protection in mice treated at 1 day or 1 week, but not
3 weeks of age (Hayward and Shreiber, 1989; Hayward
and Shriber, 1992). Lower doses (5 g/day, 5 days) af-
forded no protection in 4- and 8-week-old mice, slightly
delayed onset in 12-week-old mice, but induced re-
mission in 50%–100% of diabetic mice (Chatenoud et
al., 1992, 1994, 1997). In the neonatal high-dose studies,
immunosuppression was implicated as the key mecha-
nism of prevention (Hayward and Shriber, 1992). In con-
trast, Treg activity was implicated as a key mechanism
of remission, supported by the finding that coadmin-
istration of anti-CTLA-4 or anti-TGF-β with anti-CD3
prevented remission (Belghith et al., 2003), although
secondary effects of hyperglycemia itself might con-
tribute to anti-CD3 efficacy in diabetic animals (Kojima
et al., 2004). Thus, time- and dose-dependent varia-
tions in outcome may be partly explained by different
mechanisms of action.
Analysis of depletion data from studies on diabetic
mice may provide further insight into anti-CD3 mecha-
nisms. Using 145-2C11, high remission rates (64%–
81%) were coincident with partial T cell depletion (Cha-
tenoud et al., 1992, 1994, 1997), whereas, Mottram et
al. observed lower remission rates (14.3%) with no de-
pletion (Mottram et al., 2002). Other data suggest that
145-2C11 selectively enriches regulatory cells relative
to effector cells (Yang et al., 2004). A different anti-CD3
antibody (KT3) induced remission in diabetic NOD mice
administered low, nondepleting doses, whereas high,
fully depleting doses failed to induce remission (Mot-
tram et al., 2002). Thus, in diabetic mice, partial deple-
tion may contribute to efficacy through selective effec-
tor cell depletion and regulatory cell enrichment,
whereas complete CD3 depletion may prevent rebal-
ancing of the immune response toward a more regula-
tory state.
Immunity
122Table 3. Variability in Protocols and Reporting for Treatment of Diabetic Mice
Subject Potential Characteristics Variation within a Characteristic
Definition of diabetes Glycosuria
Plasma sampling condition Fasting, non-fasting
Glycemia level (mg/dL) 200, 300, 350, 400
Hyperglycemic reproducibility 1×, 2×, 3×
Time from initial diagnosis to treatment 1 day, <3 days, <1 week, <2 weeks, >2 weeks
Definition of efficacy Mortality
Aglycosuria
Glycemia level (mg/dL) Normal, 180, 200, 250
Independence from exogenous insulin
Reported data Death/survival
Blood glucose Endpoint, longitudinal data
Remission/diabetesAnti-CD3 clinical trials in new onset diabetic patients
have yielded promising results (Herold et al., 2002,
2005; Keymeulen et al., 2005). Unlike the mitogenic
145-2C11 antibody commonly used in NOD mice, the
clinical hOKT3γ1 (Ala-Ala) and ChAglyCD3 antibodies
are nonmitogenic Fc-mutated antibodies. Although sig-
nificant differences between the anti-CD3 agents used
in NOD versus humans preclude comparative analysis
of mechanisms of action and dosing, the inclusion of
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sTable 4. Efficacy of Clinically Tested Therapies in NOD versus Human: Comparison of Timing, Dose, and Efficacy
NOD Human
Timing and Effect Dose during Rx References Timing and Effect Dose during Rx References
Anti-CD3 Neonatal: Neonatal: (Hayward and Shreiber, Recent diab: 0.001–0.045 (Herold et al., 2002,
protection 0.20–0.25 1989; Hayward and improved C peptide mg/kg/day 2005; Keymeulen
mg once Shriber, 1992) versus placebo; et al., 2005)
reduced HbA1c,
reduced insulin
requirement versus
pretreatment
Prediab: no Prediab: 0.005 (Chatenoud et al., 1997;
protection mg/day; 0.2 Hayward and Shriber,
mg once 1992)
Diabetic: Diabetic, (Chatenoud et al., 1992,
remission and 0.005–0.05 1994, 1997; Mottram
no remission mg/day; 0.25 et al., 2002)
reported mg 1–4×/wk
Parenteral Prediab: 0.005–0.03 (Atkinson et al., 1990; Prediab: no difference 0.01 mg/kg/ (Diabetes
insulin protection mg/day; 0.22 Karounos et al., 1997; in incidence, peak C day s.c. + Prevention Trial--
mg at wks 4, Muir et al., 1995) peptide versus >0.014 mg/ Type 1 Diabetes
12, 16, 22 placebo kg i.v. Study Group,
2002)
Oral insulin Prediab: 1 mg, 1-2×/wk (Zhang et al., 1991; Prediab: similar rate in Prediab: 7.5 (Skyler et al., 2005)
protection Hartmann et al., 1997; onset mg/day
Homann et al., 1999;
Ramiya et al., 1997;
Bergerot et al., 1996)
Recent diab: no Recent diab: (Pozzilli et al., 2000;
difference in HbA1c, 2.5-7.5 mg/ Chaillous et al.,
C peptide, insulin day 2000)
requirements versus
placebo
Nasal Prediab: Dose not (Harrison et al., 1996) Prediab: no Prediab: 1.6 (Harrison et al.,
insulin protection reported, acceleration of mg/day, 2004)
1–7×/wk disease 2–7×/wk
Diabetic: no change in Diabetic: 1–6 (Skyler et al., 2001)
HbA1c, glucose, mg/day,
hypoglycemic 3×/day
events, ongoing
ition and depletion, may aid in identifying and investi-ecent diabetics is supported by the time dependency
bserved in NOD mice. As in NOD mice, more pro-
ounced response to anti-CD3 was observed in pa-
ients with greater residual β cell function, as measured
y C peptide levels. Because biomarkers for human
herapy must rely primarily upon noninvasive measure-
ents, peripheral blood measurements in preclinical
odels, including C peptide levels and cellular compo-
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123gating biomarkers indicative of likely responders, drug
activity, or therapeutic impact and thereby improve clin-
ical translation.
Other Agents Tested in Human Clinical Trials
Similar protocol discrepancies were observed in com-
parative analyses of other agents (Table S2). Azathi-
oprine, bacille Calmette-Guerin (BCG), pentoxifylline,
intravenous Ig, and linomide were only tested in predia-
betic mice, whereas corresponding clinical trials were
conducted on diabetic patients. Nicotinamide, BCG,
and linomide were administered at much lower doses
in humans than in mice on a body weight basis.
Protocol discrepancies do not account for all unex-
pected clinical results. For therapies such as nicotin-
amide and oral insulin, differential efficacy was observed
in preclinical models, with protection in prediabetic NOD
mice, but not in BB rats (Yamada et al., 1982; Zhang et
al., 1991; Hermitte et al., 1989; Mordes et al., 1996). For
future clinical trials, efforts to understand the agent-
mediated mechanisms accounting for different out-
comes may help determine which, if either, model is
more relevant to humans. Finally, species-specific dif-
ferences (Mestas and Hughes, 2004) could influence
trial outcomes. Although not all uncertainties may be
fully delineated, our analysis suggests many could be
addressed prior to human clinical trials.
Recommendations for Translational Efforts
Because timing, dose, and species-specific biology
can critically impact therapeutic efficacy, efforts to
identify and minimize such dependencies may improve
future translational efforts. Prior to human trials, the re-
lationship between therapeutic efficacy and disease
stage could be thoroughly characterized. Analysis of
dose dependency in preclinical models and thorough
characterization of drug PK/PD should guide human
dosing strategies. Additionally, blood-based measure-
ments in preclinical studies could suggest biomarkers
and facilitate comparison with clinical results. Finally,
therapies should be tested in multiple animal models;
consistent findings would increase translational confi-
dence, and inconsistencies should encourage further
analysis.
Conclusions
To our knowledge, this review represents the first ana-
lytic evaluation of interventions tested in the NOD
mouse. We illustrate that the common tenet, that most
agents prevent diabetes in NOD mice, is too simple.
Many have no effect, and some exacerbate, leading to
a reevaluation of the premise on which treatment was
predicated. Further, treatment outcomes in prediabetic
mice were found to be independent of treatment initia-
tion time, and over half of the studies on overtly dia-
betic mice reported successful endpoints. Together,
these analyses suggest that preclinical NOD data
should not be dismissed on the basis of “everything
works in NOD mice,” and more studies should be con-
ducted on late prediabetic or diabetic mice. In addition,
we observed that variations in dose and timing can
strongly influence efficacy and may explain some of thediscrepancies between NOD and human trial out-
comes. These findings argue that translational T1D
medicine will benefit from careful attention to thorough
preclinical studies and their implications. Finally, it is
our hope that the discussion and recommendations
presented herein will stimulate scientific discussion on
optimizing the value of the NOD mouse. For example,
a consensus diabetes definition would provide the
foundation for identifying correlative characteristics of
disease progression or therapeutic response between
NOD mice and humans. In fact, our current dataset may
identify such characteristics and could be the subject
of future analysis. This and other efforts to fully lever-
age preclinical resources may substantially minimize
the risks associated with translating preclinical NOD
successes to human clinical practice.
Supplemental Data
Supplemental Data include Supplemental Experimental Pro-
cedures, ten figures, and two tables and are available with this arti-
cle online at http://www.immunity.com/cgi/content/full/23/2/115/
DC1/.
Acknowledgments
We thank Dave Polidori, Vincent Hurez, Seth Michelson, Cindy
Stokes, Barry Sudbeck, Michael French, Mikhail Gishizky, and Len
Harrison for critical reviews. We also thank Ananth Kadambi for
data extraction efforts and Sheryl Stark and Christy Popp for assis-
tance in acquiring literature. This work is supported by the Ameri-
can Diabetes Association. J.A.B. has a financial interest in the
monoclonal antibody hOKT3γ1 (Ala-Ala) consisting of a patent ap-
plication and a commercial agreement with MacroGenics, Inc.
References
Akhtar, I., Gold, J.P., Pan, L.Y., Ferrara, J.L., Yang, X.D., Kim, J.I.,
and Tan, K.N. (1995). CD4+ beta islet cell-reactive T cell clones that
suppress autoimmune diabetes in nonobese diabetic mice. J. Exp.
Med. 182, 87–97.
Anderson, M.S., and Bluestone, J.A. (2004). The NOD mouse: a
model of immune dysregulation. Annu. Rev. Immunol. 23, 447–485.
Ansari, M.J., Salama, A.D., Chitnis, T., Smith, R.N., Yagita, H., Akiba,
H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S.J., et al. (2003).
The programmed death-1 (PD-1) pathway regulates autoimmune
diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198, 63–69.
Atkinson, M.A., Maclaren, N.K., and Luchetta, R. (1990). Insulitis
and diabetes in NOD mice reduced by prophylactic insulin therapy.
Diabetes 39, 933–937.
Bach, J.F., and Chatenoud, L. (2001). Tolerance to islet autoanti-
gens in type 1 diabetes. Annu. Rev. Immunol. 19, 131–161.
Baeder, W.L., Sredy, J., Sehgal, S.N., Chang, J.Y., and Adams, L.M.
(1992). Rapamycin prevents the onset of insulin-dependent diabe-
tes mellitus (IDDM) in NOD mice. Clin. Exp. Immunol. 89, 174–178.
Balasa, B., Krahl, T., Patstone, G., Lee, J., Tisch, R., McDevitt, H.O.,
and Sarvetnick, N. (1997). CD40 ligand-CD40 interactions are nec-
essary for the initiation of insulitis and diabetes in nonobese dia-
betic mice. J. Immunol. 159, 4620–4627.
Beales, P.E., Delovitch, T.L., Signore, A., and Pozzilli, P. (1996).
Standardizing experiments with NOD mice. Autoimmunity 24,
127–129.
Belghith, M., Bluestone, J.A., Barriot, S., Megret, J., Bach, J.F., and
Chatenoud, L. (2003). TGF-beta-dependent mechanisms mediate
restoration of self-tolerance induced by antibodies to CD3 in overt
autoimmune diabetes. Nat. Med. 9, 1202–1208.
Immunity
124Bendelac, A., Carnaud, C., Boitard, C., and Bach, J.F. (1987). Syn-
geneic transfer of autoimmune diabetes from diabetic NOD mice
to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T
cells. J. Exp. Med. 166, 823–832.
Bergerot, I., Fabien, N., Mayer, A., and Thivolet, C. (1996). Active
suppression of diabetes after oral administration of insulin is deter-
mined by antigen dosage. Ann. N Y Acad. Sci. 778, 362–367.
Bergerot, I., Ploix, C., Petersen, J., Moulin, V., Rask, C., Fabien, N.,
Lindblad, M., Mayer, A., Czerkinsky, C., Holmgren, J., and Thivolet,
C. (1997). A cholera toxoid-insulin conjugate as an oral vaccine
against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci.
USA 94, 4610–4614.
Bour-Jordan, H., Salomon, B.L., Thompson, H.L., Szot, G.L., Bern-
hard, M.R., and Bluestone, J.A. (2004). Costimulation controls dia-
betes by altering the balance of pathogenic and regulatory T cells.
J. Clin. Invest. 114, 979–987.
Cameron, M.J., Arreaza, G.A., Waldhauser, L., Gauldie, J., and De-
lovitch, T.L. (2000). Immunotherapy of spontaneous type 1 diabetes
in nonobese diabetic mice by systemic interleukin-4 treatment em-
ploying adenovirus vector-mediated gene transfer. Gene Ther. 7,
1840–1846.
Centers for Disease Control and Prevention. National diabetes fact
sheet: general information and national estimates on diabetes in
the United States, 2003. Rev ed. Atlanta, GA: U.S. Department of
Health and Human Services, Centers for Disease Control and Pre-
vention, 2004.
Cetkovic-Cvrlje, M., Gerling, I.C., Muir, A., Atkinson, M.A., Elliot,
J.F., and Leiter, E.H. (1997). Retardation or acceleration of diabetes
in NOD/Lt mice mediated by intrathymic administration of candi-
date beta-cell antigens. Diabetes 46, 1975–1982.
Chaillous, L., Lefevre, H., Thivolet, C., Boitard, C., Lahlou, N., Atlan-
Gepner, C., Bouhanick, B., Mogenet, A., Nicolino, M., Carel, J.C., et
al. (2000). Oral insulin administration and residual beta-cell function
in recent-onset type 1 diabetes: a multicentre randomised con-
trolled trial. Diabete Insuline Orale group. Lancet 356, 545–549.
Chang, Y., and Prud’homme, G.J. (1999). Intramuscular administra-
tion of expression plasmids encoding interferon-gamma receptor/
IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J.
Gene Med. 1, 415–423.
Chatenoud, L., Thervet, E., Primo, J., and Bach, J.F. (1992). [Re-
mission of established disease in diabetic NOD mice induced by
anti-CD3 monoclonal antibody]. C. R. Acad. Sci. III 315, 225–228.
Chatenoud, L., Thervet, E., Primo, J., and Bach, J.F. (1994). Anti-
CD3 antibody induces long-term remission of overt autoimmunity
in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91, 123–127.
Chatenoud, L., Primo, J., and Bach, J.F. (1997). CD3 antibody-
induced dominant self tolerance in overtly diabetic NOD mice. J.
Immunol. 158, 2947–2954.
Classen, J.B. (1996). The timing of immunization affects the devel-
opment of diabetes in rodents. Autoimmunity 24, 137–145.
Delovitch, T.L., and Singh, B. (1997). The nonobese diabetic mouse
as a model of autoimmune diabetes: immune dysregulation gets
the NOD. Immunity 7, 727–738.
Diabetes Prevention Trial--Type 1 Diabetes Study Group (2002). Ef-
fects of insulin in relatives of patients with type 1 diabetes mellitus.
N. Engl. J. Med. 346, 1685–1691.
Feili-Hariri, M., Falkner, D.H., Gambotto, A., Papworth, G.D., Wat-
kins, S.C., Robbins, P.D., and Morel, P.A. (2003). Dendritic cells
transduced to express interleukin-4 prevent diabetes in nonobese
diabetic mice with advanced insulitis. Hum. Gene Ther. 14, 13–23.
Fujihira, K., Nagata, M., Moriyama, H., Yasuda, H., Arisawa, K., Na-
kayama, M., Maeda, S., Kasuga, M., Okumura, K., Yagita, H., and
Yokono, K. (2000). Suppression and acceleration of autoimmune
diabetes by neutralization of endogenous interleukin-12 in NOD
mice. Diabetes 49, 1998–2006.
Funda, D.P., Hartoft-Nielsen, M.L., Kaas, A., and Buschard, K.
(1998). Effect of intrathymic administration of mycobacterial heat
shock protein 65 and peptide p277 on the development of diabetes
i
1
G
M
M
m
m
G
T
b
i
1
J
H
o
i
p
H
K
c
1
H
E
b
i
D
H
(
t
t
H
y
2
H
a
s
H
i
n
H
C
T
J
H
m
v
H
L
a
o
H
s
B
t
t
o
H
r
a
1
I
S
a
o
f
I
d
N
Jn NOD mice: caution required in vaccination studies. APMIS 106,
009–1016.
oudy, K., Song, S., Wasserfall, C., Zhang, Y.C., Kapturczak, M.,
uir, A., Powers, M., Scott-Jorgensen, M., Campbell-Thompson,
., Crawford, J.M., et al. (2001). Adeno-associated virus vector-
ediated IL-10 gene delivery prevents type 1 diabetes in NOD
ice. Proc. Natl. Acad. Sci. USA 98, 13913–13918.
oudy, K.S., Burkhardt, B.R., Wasserfall, C., Song, S., Campbell-
hompson, M.L., Brusko, T., Powers, M.A., Clare-Salzler, M.J., So-
el, E.S., Ellis, T.M., et al. (2003). Systemic overexpression of IL-10
nduces CD4+CD25+ cell populations in vivo and ameliorates type
diabetes in nonobese diabetic mice in a dose-dependent fashion.
. Immunol. 171, 2270–2278.
an, H.S., Jun, H.S., Utsugi, T., and Yoon, J.W. (1996). A new type
f CD4+ suppressor T cell completely prevents spontaneous auto-
mmune diabetes and recurrent diabetes in syngeneic islet-trans-
lanted NOD mice. J. Autoimmun. 9, 331–339.
arrison, L.C., Dempsey-Collier, M., Kramer, D.R., and Takahashi,
. (1996). Aerosol insulin induces regulatory CD8 gamma delta T
ells that prevent murine insulin-dependent diabetes. J. Exp. Med.
84, 2167–2174.
arrison, L.C., Honeyman, M.C., Steele, C.E., Stone, N.L., Sarugeri,
., Bonifacio, E., Couper, J.J., and Colman, P.G. (2004). Pancreatic
eta-cell function and immune responses to insulin after admin-
stration of intranasal insulin to humans at risk for type 1 diabetes.
iabetes Care 27, 2348–2355.
artmann, B., Bellmann, K., Ghiea, I., Kleemann, R., and Kolb, H.
1997). Oral insulin for diabetes prevention in NOD mice: potentia-
ion by enhancing Th2 cytokine expression in the gut through bac-
erial adjuvant. Diabetologia 40, 902–909.
askins, K., and McDuffie, M. (1990). Acceleration of diabetes in
oung NOD mice with a CD4+ islet-specific T cell clone. Science
49, 1433–1436.
ayward, A.R., and Shreiber, M. (1989). Neonatal injection of CD3
ntibody into nonobese diabetic mice reduces the incidence of in-
ulitis and diabetes. J. Immunol. 143, 1555–1559.
ayward, A.R., and Shriber, M. (1992). Reduced incidence of insul-
tis in NOD mice following anti-CD3 injection: requirement for neo-
atal injection. J. Autoimmun. 5, 59–67.
ealey, D., Ozegbe, P., Arden, S., Chandler, P., Hutton, J., and
ooke, A. (1995). In vivo activity and in vitro specificity of CD4+
h1 and Th2 cells derived from the spleens of diabetic NOD mice.
. Clin. Invest. 95, 2979–2985.
ermitte, L., Vialettes, B., Atlef, N., Payan, M.J., Doll, N., Schei-
ann, A., and Vague, P. (1989). High dose nicotinamide fails to pre-
ent diabetes in BB rats. Autoimmunity 5, 79–86.
erold, K.C., Hagopian, W., Auger, J.A., Poumian-Ruiz, E., Taylor,
., Donaldson, D., Gitelman, S.E., Harlan, D.M., Xu, D., Zivin, R.A.,
nd Bluestone, J.A. (2002). Anti-CD3 monoclonal antibody in new-
nset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698.
erold, K.C., Gitelman, S.E., Masharani, U., Hagopian, W., Bisikir-
ka, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D.M., and
luestone, J.A. (2005). A single course of anti-CD3 monoclonal an-
ibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-pep-
ide responses and clinical parameters for at least 2 years after
nset of type 1 diabetes. Diabetes 54, 1763–1769.
omann, D., Dyrberg, T., Petersen, J., Oldstone, M.B., and von Her-
ath, M.G. (1999). Insulin in oral immune “tolerance”: a one-amino
cid change in the B chain makes the difference. J. Immunol. 163,
833–1838.
guchi, M., Inagawa, H., Nishizawa, T., Okutomi, T., Morikawa, A.,
oma, G.I., and Mizuno, D. (1992). Homeostasis as regulated by
ctivated macrophage. V. Suppression of diabetes mellitus in non-
bese diabetic mice by LPSw (a lipopolysaccharide from wheat
lour). Chem. Pharm. Bull. (Tokyo) 40, 1004–1006.
to, A., Aoyanagi, N., and Maki, T. (1997). Regulation of autoimmune
iabetes by interleukin 3-dependent bone marrow-derived cells in
OD mice. J. Autoimmun. 10, 331–338.
acob, C.O., Aiso, S., Michie, S.A., McDevitt, H.O., and Acha-Orbea,
Review
125H. (1990). Prevention of diabetes in nonobese diabetic mice by tu-
mor necrosis factor (TNF): similarities between TNF-alpha and in-
terleukin 1. Proc. Natl. Acad. Sci. USA 87, 968–972.
Karounos, D.G. (2003). Dose of insulin is a critical factor in the pre-
vention of Type 1 diabetes in the NOD mouse. Diabetes 52, A276.
Karounos, D.G., Bryson, J.S., and Cohen, D.A. (1997). Metabolically
inactive insulin analog prevents type I diabetes in prediabetic NOD
mice. J. Clin. Invest. 100, 1344–1348.
Katz, J.D., Benoist, C., and Mathis, D. (1995). T helper cell subsets
in insulin-dependent diabetes. Science 268, 1185–1188.
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A.G., Mathieu, C.,
Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon,
S., et al. (2005). Insulin needs after CD3-antibody therapy in new-
onset type 1 diabetes. N. Engl. J. Med. 352, 2598–2608.
Kim, J.Y., Chi, J.K., Kim, E.J., Park, S.Y., Kim, Y.W., and Lee, S.K.
(1997). Inhibition of diabetes in non-obese diabetic mice by nicotin-
amide treatment for 5 weeks at the early age. J. Korean Med. Sci.
12, 293–297.
Kojima, H., Fujimiya, M., Matsumura, K., Nakahara, T., Hara, M., and
Chan, L. (2004). Extrapancreatic insulin-producing cells in multiple
organs in diabetes. Proc. Natl. Acad. Sci. USA 101, 2458–2463.
Lenschow, D.J., Ho, S.C., Sattar, H., Rhee, L., Gray, G., Nabavi, N.,
Herold, K.C., and Bluestone, J.A. (1995). Differential effects of anti-
B7-1 and anti-B7-2 monoclonal antibody treatment on the develop-
ment of diabetes in the nonobese diabetic mouse. J. Exp. Med.
181, 1145–1155.
Lohr, J., Knoechel, B., Jiang, S., Sharpe, A.H., and Abbas, A.K.
(2003). The inhibitory function of B7 costimulators in T cell re-
sponses to foreign and self-antigens. Nat. Immunol. 4, 664–669.
Mahmood, I. (1999). Allometric issues in drug development. J.
Pharm. Sci. 88, 1101–1106.
Makhlouf, L., Grey, S.T., Dong, V., Csizmadia, E., Arvelo, M.B.,
Auchincloss, H., Jr., Ferran, C., and Sayegh, M.H. (2004). Depleting
anti-CD4 monoclonal antibody cures new-onset diabetes, prevents
recurrent autoimmune diabetes, and delays allograft rejection in
nonobese diabetic mice. Transplantation 77, 990–997.
Maki, T., Ichikawa, T., Blanco, R., and Porter, J. (1992). Long-term
abrogation of autoimmune diabetes in nonobese diabetic mice by
immunotherapy with anti-lymphocyte serum. Proc. Natl. Acad. Sci.
USA 89, 3434–3438.
Makino, S., Kunimoto, K., Muraoka, Y., Mizushima, Y., Katagiri, K.,
and Tochino, Y. (1980). Breeding of a non-obese, diabetic strain of
mice. Jikken Dobutsu 29, 1–13.
Melo, M.E., Qian, J., El Amine, M., Agarwal, R.K., Soukhareva, N.,
Kang, Y., and Scott, D.W. (2002). Gene transfer of Ig-fusion proteins
into B cells prevents and treats autoimmune diseases. J. Immunol.
168, 4788–4795.
Menard, V., Jacobs, H., Jun, H.S., Yoon, J.W., and Kim, S.W. (1999).
Anti-GAD monoclonal antibody delays the onset of diabetes melli-
tus in NOD mice. Pharm. Res. 16, 1059–1066.
Mestas, J., and Hughes, C.C. (2004). Of mice and not men: differ-
ences between mouse and human immunology. J. Immunol. 172,
2731–2738.
Monetini, L., Cavallo, M.G., Sarugeri, E., Sentinelli, F., Stefanini, L.,
Bosi, E., Thorpe, R., and Pozzilli, P. (2004). Cytokine profile and
insulin antibody IgG subclasses in patients with recent onset type
1 diabetes treated with oral insulin. Diabetologia 47, 1795–1802.
Mordes, J.P., Schirf, B., Roipko, D., Greiner, D.L., Weiner, H., Nel-
son, P., and Rossini, A.A. (1996). Oral insulin does not prevent insu-
lin-dependent diabetes mellitus in BB rats. Ann. N Y Acad. Sci. 778,
418–421.
Mordes, J.P., Bortell, R., Blankenhorn, E.P., Rossini, A.A., and
Greiner, D.L. (2004). Rat models of type 1 diabetes: genetics, envi-
ronment, and autoimmunity. ILAR J. 45, 278–291.
Mori, Y., Suko, M., Okudaira, H., Matsuba, I., Tsuruoka, A., Sasaki,
A., Yokoyama, H., Tanase, T., Shida, T., and Nishimura, M. (1986).
Preventive effects of cyclosporin on diabetes in NOD mice. Diabe-
tologia 29, 244–247.
Mottram, P.L., Murray-Segal, L.J., Han, W., Maguire, J., and Stein-Oakley, A.N. (2002). Remission and pancreas isograft survival in
recent onset diabetic NOD mice after treatment with low-dose anti-
CD3 monoclonal antibodies. Transpl. Immunol. 10, 63–72.
Muir, A., Peck, A., Clare-Salzler, M., Song, Y.H., Cornelius, J.,
Luchetta, R., Krischer, J., and Maclaren, N. (1995). Insulin immuni-
zation of nonobese diabetic mice induces a protective insulitis
characterized by diminished intraislet interferon-gamma transcrip-
tion. J. Clin. Invest. 95, 628–634.
Nicoletti, F., Di Marco, R., Zaccone, P., Magro, G., Di Mauro, M.,
Grasso, S., and Meroni, P.L. (1999a). Endogenous interleukin-12
only plays a key pathogenetic role in non-obese diabetic mouse
diabetes during the very early stages of the disease. Immunology
97, 367–370.
Nicoletti, F., Zaccone, P., Conget, I., Gomis, R., Moller, C., Meroni,
P.L., Bendtzen, K., Trepicchio, W., and Sandler, S. (1999b). Early
prophylaxis with recombinant human interleukin-11 prevents spon-
taneous diabetes in NOD mice. Diabetes 48, 2333–2339.
Nitta, Y., Tashiro, F., Tokui, M., Shimada, A., Takei, I., Tabayashi,
K., and Miyazaki, J. (1998). Systemic delivery of interleukin 10 by
intramuscular injection of expression plasmid DNA prevents auto-
immune diabetes in nonobese diabetic mice. Hum. Gene Ther. 9,
1701–1707.
O’Hara, R.M., Jr., Henderson, S.L., and Nagelin, A. (1996). Preven-
tion of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD
mice. Ann. N Y Acad. Sci. 795, 241–249.
O’Shea, J.J., Ma, A., and Lipsky, P. (2002). Cytokines and autoim-
munity. Nat. Rev. Immunol. 2, 37–45.
Pakala, S.V., Kurrer, M.O., and Katz, J.D. (1997). T helper 2 (Th2) T
cells induce acute pancreatitis and diabetes in immune-compro-
mised nonobese diabetic (NOD) mice. J. Exp. Med. 186, 299–306.
Paust, S., Lu, L., McCarty, N., and Cantor, H. (2004). Engagement
of B7 on effector T cells by regulatory T cells prevents autoimmune
disease. Proc. Natl. Acad. Sci. USA 101, 10398–10403.
Pennline, K.J., Roque-Gaffney, E., and Monahan, M. (1994). Re-
combinant human IL-10 prevents the onset of diabetes in the non-
obese diabetic mouse. Clin. Immunol. Immunopathol. 71, 169–175.
Peterson, J.D., and Haskins, K. (1996). Transfer of diabetes in the
NOD-scid mouse by CD4 T-cell clones. Differential requirement for
CD8 T-cells. Diabetes 45, 328–336.
Peterson, K.P., Van Hirtum, M., and Peterson, C.M. (1997). Dapsone
decreases the cumulative incidence of diabetes in non-obese dia-
betic female mice. Proc. Soc. Exp. Biol. Med. 215, 264–268.
Poulin, M., and Haskins, K. (2000). Induction of diabetes in non-
obese diabetic mice by Th2 T cell clones from a TCR transgenic
mouse. J. Immunol. 164, 3072–3078.
Pozzilli, P., Pitocco, D., Visalli, N., Cavallo, M.G., Buzzetti, R., Crino,
A., Spera, S., Suraci, C., Multari, G., Cervoni, M., et al. (2000). No
effect of oral insulin on residual beta-cell function in recent-onset
type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 43,
1000–1004.
Ramiya, V.K., Shang, X.Z., Wasserfall, C.H., and Maclaren, N.K.
(1997). Effect of oral and intravenous insulin and glutamic acid de-
carboxylase in NOD mice. Autoimmunity 26, 139–151.
Reddy, S., Bibby, N.J., and Elliott, R.B. (1990). Early nicotinamide
treatment in the NOD mouse: effects on diabetes and insulitis sup-
pression and autoantibody levels. Diabetes Res. 15, 95–102.
Roep, B.O., Atkinson, M., and von Herrath, M. (2004). Satisfaction
(not) guaranteed: re-evaluating the use of animal models of type 1
diabetes. Nat. Rev. Immunol. 4, 989–997.
Rosenbloom, A.L., Schatz, D.A., Krischer, J.P., Skyler, J.S., Becker,
D.J., Laporte, R.E., Libman, I., Pietropaolo, M., Dosch, H.M., Fin-
berg, L., et al. (2000). Therapeutic controversy: prevention and
treatment of diabetes in children. J. Clin. Endocrinol. Metab. 85,
494–522.
Salomon, B., and Bluestone, J.A. (2001). Complexities of CD28/B7:
CTLA-4 costimulatory pathways in autoimmunity and transplanta-
tion. Annu. Rev. Immunol. 19, 225–252.
Salomon, B., Lenschow, D.J., Rhee, L., Ashourian, N., Singh, B.,
Sharpe, A., and Bluestone, J.A. (2000). B7/CD28 costimulation is
Immunity
126essential for the homeostasis of the CD4+CD25+ immunoregula-
tory T cells that control autoimmune diabetes. Immunity 12, 431–
440.
Satoh, J., Seino, H., Abo, T., Tanaka, S., Shintani, S., Ohta, S., Ta-
mura, K., Sawai, T., Nobunaga, T., Oteki, T., et al. (1989). Recombi-
nant human tumor necrosis factor alpha suppresses autoimmune
diabetes in nonobese diabetic mice. J. Clin. Invest. 84, 1345–1348.
Seino, H., Satoh, J., Shintani, S., Takahashi, K., Zhu, X.P., Masuda,
T., Nobunaga, T., Saito, M., Terano, Y., and Toyota, T. (1991). Inhibi-
tion of autoimmune diabetes in NOD mice with serum from strepto-
coccal preparation (OK-432)-injected mice. Clin. Exp. Immunol. 86,
413–418.
Shinomiya, M., Fazle Akbar, S.M., Shinomiya, H., and Onji, M.
(1999). Transfer of dendritic cells (DC) ex vivo stimulated with in-
terferon-gamma (IFN-gamma) down-modulates autoimmune dia-
betes in non-obese diabetic (NOD) mice. Clin. Exp. Immunol. 117,
38–43.
Shizuru, J.A., Taylor-Edwards, C., Banks, B.A., Gregory, A.K., and
Fathman, C.G. (1988). Immunotherapy of the nonobese diabetic
mouse: treatment with an antibody to T-helper lymphocytes. Sci-
ence 240, 659–662.
Skyler, J.S., Cefalu, W.T., Kourides, I.A., Landschulz, W.H., Balag-
tas, C.C., Cheng, S.L., and Gelfand, R.A. (2001). Efficacy of inhaled
human insulin in type 1 diabetes mellitus: a randomised proof-of-
concept study. Lancet 357, 331–335.
Skyler, J.S., Krischer, J.P., Wolfsdorf, J., Cowie, C., Palmer, J.P.,
Greenbaum, C., Cuthbertson, D., Rafkin-Mervis, L.E., Chase, H.P.,
and Leschek, E. (2005). Effects of oral insulin in relatives of patients
with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabe-
tes Care 28, 1068–1076.
Slavin, A.J., Maron, R., and Weiner, H.L. (2001). Mucosal admin-
istration of IL-10 enhances oral tolerance in autoimmune encepha-
lomyelitis and diabetes. Int. Immunol. 13, 825–833.
Song, S., Goudy, K., Campbell-Thompson, M., Wasserfall, C.,
Scott-Jorgensen, M., Wang, J., Tang, Q., Crawford, J.M., Ellis, T.M.,
Atkinson, M.A., and Flotte, T.R. (2004). Recombinant adeno-associ-
ated virus-mediated alpha-1 antitrypsin gene therapy prevents type
I diabetes in NOD mice. Gene Ther. 11, 181–186.
Takahashi, M., Kojima, S., Yamaoka, K., and Niki, E. (2000). Preven-
tion of type I diabetes by low-dose gamma irradiation in NOD mice.
Radiat. Res. 154, 680–685.
Tang, Q., Henriksen, K.J., Boden, E.K., Tooley, A.J., Ye, J., Subudhi,
S.K., Zheng, X.X., Strom, T.B., and Bluestone, J.A. (2003). Cutting
edge: CD28 controls peripheral homeostasis of CD4+CD25+ regu-
latory T cells. J. Immunol. 171, 3348–3352.
Tang, Q., Henriksen, K.J., Bi, M., Finger, E.B., Szot, G., Ye, J., Mas-
teller, E.L., McDevitt, H., Bonyhadi, M., and Bluestone, J.A. (2004).
In vitro-expanded antigen-specific regulatory T cells suppress au-
toimmune diabetes. J. Exp. Med. 199, 1455–1465.
Thivolet, C., Bendelac, A., Bedossa, P., Bach, J.F., and Carnaud, C.
(1991). CD8+ T cell homing to the pancreas in the nonobese dia-
betic mouse is CD4+ T cell-dependent. J. Immunol. 146, 85–88.
Tominaga, Y., Nagata, M., Yasuda, H., Okamoto, N., Arisawa, K.,
Moriyama, H., Miki, M., Yokono, K., and Kasuga, M. (1998). Admin-
istration of IL-4 prevents autoimmune diabetes but enhances pan-
creatic insulitis in NOD mice. Clin. Immunol. Immunopathol. 86,
209–218.
Trembleau, S., Penna, G., Bosi, E., Mortara, A., Gately, M.K., and
Adorini, L. (1995). Interleukin 12 administration induces T helper
type 1 cells and accelerates autoimmune diabetes in NOD mice. J.
Exp. Med. 181, 817–821.
Trembleau, S., Penna, G., Gregori, S., Gately, M.K., and Adorini, L.
(1997). Deviation of pancreas-infiltrating cells to Th2 by interleukin-
12 antagonist administration inhibits autoimmune diabetes. Eur. J.
Immunol. 27, 2330–2339.
Trembleau, S., Penna, G., Gregori, S., Magistrelli, G., Isacchi, A.,
and Adorini, L. (2000). Early Th1 response in unprimed nonobese
diabetic mice to the tyrosine phosphatase-like insulinoma-associ-
ated protein 2, an autoantigen in type 1 diabetes. J. Immunol. 165,
6748–6755.
T
n
(
c
i
2
W
X
i
d
W
a
t
i
W
n
m
Y
(
d
b
1
Y
a
d
A
7
Y
(
c
b
Y
S
f
I
p
Y
M
d
Y
T
t
Z
D
m
o
Z
S
i
1
Z
s
n
t
Isukamoto, K., Yokono, K., Amano, K., Nagata, M., Yagi, N., Tomi-
aga, Y., Moriyama, H., Miki, M., Okamoto, N., Yoneda, R., et al.
1995). Administration of monoclonal antibodies against vascular
ell adhesion molecule-1/very late antigen-4 abrogates predispos-
ng autoimmune diabetes in NOD mice. Cell. Immunol. 165, 193–
01.
illiams, A.J., Beales, P.E., Krug, J., Procaccini, E., Signore, A.,
u, S., Gale, E.A., and Pozzilli, P. (1993). Tolbutamide reduces the
ncidence of diabetes mellitus, but not insulitis, in the non-obese-
iabetic mouse. Diabetologia 36, 487–492.
ilson, S.S., White, T.C., and DeLuca, D. (2001). Therapeutic alter-
tion of insulin-dependent diabetes mellitus progression by T cell
olerance to glutamic acid decarboxylase 65 peptides in vitro and
n vivo. J. Immunol. 167, 569–577.
u, A.J., Hua, H., Munson, S.H., and McDevitt, H.O. (2002). Tumor
ecrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD
ice. Proc. Natl. Acad. Sci. USA 99, 12287–12292.
agi, H., Matsumoto, M., Kishimoto, Y., Makino, S., and Harada, M.
1991). Possible mechanism of the preventive effect of BCG against
iabetes mellitus in NOD mouse. II. Suppression of pathogenesis
y macrophage transfer from BCG-vaccinated mice. Cell. Immunol.
38, 142–149.
amada, K., Nonaka, K., Hanafusa, T., Miyazaki, A., Toyoshima, H.,
nd Tarui, S. (1982). Preventive and therapeutic effects of large-
ose nicotinamide injections on diabetes associated with insulitis.
n observation in nonobese diabetic (NOD) mice. Diabetes 31,
49–753.
ang, W., Hussain, S., Mi, Q.S., Santamaria, P., and Delovitch, T.L.
2004). Perturbed homeostasis of peripheral T cells elicits de-
reased susceptibility to anti-CD3-induced apoptosis in predia-
etic nonobese diabetic mice. J. Immunol. 173, 4407–4416.
ang, X.D., Tisch, R., Singer, S.M., Cao, Z.A., Liblau, R.S.,
chreiber, R.D., and McDevitt, H.O. (1994). Effect of tumor necrosis
actor alpha on insulin-dependent diabetes mellitus in NOD mice.
. The early development of autoimmunity and the diabetogenic
rocess. J. Exp. Med. 180, 995–1004.
ang, Z., Chen, M., Wu, R., Fialkow, L.B., Bromberg, J.S., McDuffie,
., Naji, A., and Nadler, J.L. (2002a). Suppression of autoimmune
iabetes by viral IL-10 gene transfer. J. Immunol. 168, 6479–6485.
ang, Z.D., Chen, M., Wu, R., McDuffie, M., and Nadler, J.L. (2002b).
he anti-inflammatory compound lisofylline prevents Type I diabe-
es in non-obese diabetic mice. Diabetologia 45, 1307–1314.
accone, P., Fehervari, Z., Jones, F.M., Sidobre, S., Kronenberg, M.,
unne, D.W., and Cooke, A. (2003). Schistosoma mansoni antigens
odulate the activity of the innate immune response and prevent
nset of type 1 diabetes. Eur. J. Immunol. 33, 1439–1449.
hang, Z.J., Davidson, L., Eisenbarth, G., and Weiner, H.L. (1991).
uppression of diabetes in nonobese diabetic mice by oral admin-
stration of porcine insulin. Proc. Natl. Acad. Sci. USA 88, 10252–
0256.
heng, X.X., Steele, A.W., Hancock, W.W., Stevens, A.C., Nicker-
on, P.W., Roy-Chaudhury, P., Tian, Y., and Strom, T.B. (1997). A
oncytolytic IL-10/Fc fusion protein prevents diabetes, blocks au-
oimmunity, and promotes suppressor phenomena in NOD mice. J.
mmunol. 158, 4507–4513.
